Startups
Affibody is a Swedish biotech company developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Overview
Location
Burkina Faso, Sahel, Solna
Employees
11-50
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Acelyrin raises $250M, licenses antibody drug that could rival Novartis, Lilly meds | Nearly a year ago, biotech startup Acelyrin emerged with two industry veterans at the helm, an unspecified amount of funding, and plans to in-license drug candidates with an initial focus on immunology. The company played its cards close to... |
Reviews 0
FAQ about Affibody AB
What has the press written about Affibody AB?
Parsers VC has collected 2 articles mentioning Affibody AB, among them “Acelyrin raises $250M, licenses antibody drug that could rival Novartis, Lilly meds”.
Is Affibody AB still active?
Yes, Affibody AB is active; its latest activity on Parsers VC dates from Sep 13, 2022.